anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to medicine, in particular to medications for treating blood losses, hypoxic and ischemic states, for improving a blood oxygen supply and for preserving isolated perfused organs and tissues. The inventive medical emulsion of perfluororganic compounds comprises rapidly excretable pеrfluororganic compounds such as perfluordecalin, perfluoroctylbromide, a perfluororganic additive embodied in the form of a mixture of perfluorinated tertiary amines and phospholipids in the form of a water-salt dispersion. Said perfluordecalin and perfluoroctylbromide are contained in the composition of the rapidly excretable perfluororganic compounds at a ratio ranging from 10:1 to . The mixture of perfluorinated tertiary amines is embodied in the form of the mixture of perfluorotripropylamine and the coproducts thereof: cis-and trans-isomers perfluor-1-propyl 3,4-dimethylpyrrolidone and perfluor-1-propyl-4-methylpiperidine. The inventive method for producing the emulsion consists in producing the water-salt dispersion of phospholipids, in homogenizing the perfluororganic compounds therein at a high pressure and in heat sterilization of the final emulsion. The storage life of the inventive emulsion in the unfrozen state thereof at a temperature of +4°С is equal to at least 6 months during which the biocompatibility of said emulsion with a biological medium (blood, plasma or serum) is preserved.
A substantial percentage of individuals with bulimia nervosa (BN) also meet criteria for a co-occurring substance use disorder, such as alcohol abuse or dependence; however, research examining this sub-group of patients with BN is limited. Understanding characteristics common to both eating and alcohol use disorders may enhance our understanding of the mechanisms that could contribute to the co-occurrence and perpetuation of these disorders. The primary aim of the current study is to compare patients with BN with and without an alcohol use disorder and normal controls on computer-administered and paper-and-pencil assessments and in two laboratory test meals (a binge meal and a normal meal) on separate days. Participants will also complete self-report and interview measures of eating disorder symptoms and alcohol consumption. By probing the underpinnings of BN and alcohol use disorders, we can determine whether these disorders have a shared diathesis, which will lay an essential foundation for future research to examine biological and genetic correlates of these disorders. Finally, as little is known about the treatment of patients with BN and a co occurring alcohol use disorder, an exploratory aim of the current study is to evaluate the suitability and efficacy of a 20-session cognitive-behavioral treatment (CBT) addressing both bulimic symptoms and alcohol use.
Several embodiments of medication administrator record keeping systems (MAR Systems). The MAR systems include MAR forms and a writing system adapted to permit health care providers to write onto the forms and to electronically capture pen stroke information corresponding to the written information. The MAR forms are associated with specific patients. The penstroke information is used to update an image of the MAR forms. The pen stroke information is also used to update information in a MAR database module. The MAR database module may be updated manually be a technician or automatically by a MAR data processing module. Some MAR forms may include action fields that trigger an action. For example, some MAR forms include a reorder action field that triggers a process of reordering meds for a patient.
PURPOSE:To obtain a new substance, having antimicrobial and antitumor activities and useful as an antitumor agent. CONSTITUTION:A substance, WS64826, or its salt. appearance: red powder; molecular formula: C39H47NO16; molecular weight: 785; solubility: soluble in methanol, acetone, etc., slightly soluble in water and insoluble in n-hexane; color reaction: positive to the cerium acetate reaction, Molisch reaction, etc., and negative to the ninhydrin reaction and Dragendorff reaction and essential properties: amphoteric substance. This substance is obtained by culturing a strain, belonging to the genus Streptomyces and capable of producing the substance WS64826 [e.g. Streptomyces sp. No 64826 (FERM BP-3876) which is a new microorganism] in a nutrient culture medium usually under aerobic conditions and recovering the substance from the culture solution. Furthermore, the culturing is preferably carried out at 20-30 deg.C for 50-150hr.
BACKGROUND: Ventricular tachycardia is an irregular heartbeat conventionally treated using invasive cardiac catheter ablation and medication. However, when standard treatments have been exhausted, cardiac SABR provides a final treatment option to this high-mortality condition. Complex diagnostic mapping and planning scans enable multi-disciplinary target delineation for a 25Gy single fraction. However, organs at risk (OAR) near the target make this treatment challenging to plan and deliver. Publications from cardiologists report the efficacy of cardiac SABR, however there is limited data on the treatment delivery and image matching of this complex procedure.
METHODS: Four specialist therapeutic radiographers experienced in cardiac SABR reviewed 40 CBCTs from 10 patients treated in the UK. Each therapeutic radiographer conducted five image matches: a manual match (manual), an automatic match to the heart structure (auto) and the auto match followed by manual adjustment to the PTV (PTV), all using three degrees of freedom (DoF) only. The auto and PTV matches were also repeated using 6DoF. Inter-observer variability was quantified using 95% limits of agreement from a modified Bland-Altman analysis.
RESULTS: The limits of agreement were smallest in the automatic matches suggesting the algorithm is reliable. A manual adjustment from the auto match to the PTV is clinically appropriate to optimise target coverage. The limits of agreement were smaller in the 6DoF PTV match 1.06 mm, 1.24 mm, 1.68 mm than the 3DoF PTV match 1.57 mm, 2.06 mm, 2.11 mm (lateral, vertical, longitudinal).
CONCLUSION: The 6DoF CBCT image match has less variability and therefore suggest using a 6DoF couch for treatment delivery.
IMPLICATIONS FOR PRACTICE: Cardiac SABR CBCT image matching at treatment delivery is complex, optimisation of CBCT acquisition parameters and therapeutic radiographer training is essential prior to implementation.
The invention relates to a scar-removing whitening beautifying mask which is prepared from 1000g of honey and 250g of royal jelly. Generally, an optimal fermentation time is from May each year, and a fermentation period is 6 months (half a year). The mask is obtained after the fermentation period. According to the invention, 100g of honey and 250g of royal jelly are added into a sealable bottle, and are uniformly mixed by stirring. Generally, an optimal fermentation initiation season is May each year. The honey and royal jelly are uniformly mixed by stirring, and the mixture is sealed and preserved. Under a maintained temperature of 30-35 DEG C, from a period of May to August which is a crucial period, the sealed and mixed mixture of honey and royal jelly is ventilated every 10 days, such that deflation is carried out (until no gas leakage sound is produced), and the mixture is subjected to aerobic respiration; and the mixture is sealed, and fermentation is continued. Deflation and aerobic respiration are carried out every 10 days, until August is reached. In the following 3 months of fermentation, deflation and aerobic respiration are carried out according to specific situations until November (to which the half year of fermentation period is completed), and the scar-removing whitening beautifying mask is obtained by natural fermentation. The mask provided by the invention is prepared with natural raw materials and with a cyclic fermentation principle. The mask has substantial effect of removing scars, removing spots, removing blackheads, whitening, beautifying, moisturizing, and retarding skin aging.
This invention relates to a novel method for the chemical preparation of epirubicin or acid addition salts thereof, in particular the HCl salt, from daunorubicin. This process avoids the disadvantages of the prior art. First daunorubicin is methanolized to obtain daunomycinone and dauriosamine methyl ether in very high yields. Daunomycinone is converted to 14-acetoxy daunomycinone by bromination and acetoxylation, while daunosamine methyl ether is converted into an N-protected 4'-epi daunosamirie. The choice of the protecting group of the amino group of the daunosamine methyl ether is important because it has to be removed after coupling the sugar with the aglycone without causing side reactions of the aglycone. Two protecting groups were selected: the trifluoroacetyl group and the allyloxycarbonyl group. After coupling the 14-acetoxy daunomycinone with the N-protected 4'-epi daunosamine, the obtained compound was converted to epirubicin; for the latter conversion two routes were developed, depending on the amino-protecting group.
As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medication, and underlying disease. For these reasons, comparison of the incidence of antibodies to ADMELOG in the studies described below with the incidence of antibodies in other studies or to other insulin products may be misleading.

In a 52-week study of ADMELOG in type 1 diabetes patients, 49.4% were positive at baseline and 22.6% had treatment-emergent ADA (i.e., either new ADA, or increase in titer of at least 4-fold).

In a 26-week study of ADMELOG in type 2 diabetes patients, 26.4% were positive at baseline and 18.8% had treatment-emergent ADA (i.e., either new ADA, or increase in titer of at least 4-fold).
Inflammation is the primary driver of skeletal muscle wasting, with oxidative stress serving as both a major consequence and a contributor to its deleterious effects. In this regard, regulation of both can efficiently prevent atrophy and thus will increase the rate of survival [1]. With this idea, we hypothesize that preincubation of Cinnamaldehyde (CNA), a known compound with anti-oxidative and anti-inflammatory properties, may be able to prevent skeletal muscle loss. To examine the same, C2C12 post-differentiated myotubes were treated with 25 ng/ml Tumor necrosis factor-alpha (TNF-α) in the presence or absence of 50 μM CNA. The data showed that TNF-α mediated myotube thinning and a lower fusion index were prevented by CNA supplementation 4 h before TNF-α treatment. Moreover, a lower level of ROS and thus maintained antioxidant defense system further underlines the antioxidative function of CNA in atrophic conditions. CNA preincubation also inhibited an increase in the level of inflammatory cytokines and thus led to a lower level of inflammation even in the presence of TNF-α. With decreased oxidative stress and inflammation by CNA, it was able to maintain the intracellular level of injury markers (CK, LDH) and SDH activity of mitochondria. In addition, CNA modulates all five proteolytic systems [cathepsin-L, UPS (atrogin-1), calpain, LC3, beclin] simultaneously with an upregulation of Akt/mTOR pathway, in turn, preserves the muscle-specific proteins (MHCf) from degradation by TNF-α. Altogether, our study exhibits attenuation of muscle loss and provides insight into the possible mechanism of action of CNA in curbing TNF-α induced muscle loss, specifically its effect on proteolysis and protein synthesis.
In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol up to 16mg sublingually over an up to 8 hour induction window. "Buprenorphine tolerability" will be defined as pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper.
Methods and Systems implement patient management. In some cases, a patient management system  200  may include one or more respiratory pressure therapy devices to deliver respiratory pressure therapy to patients, and generate therapy data relating to a therapy session for a patient. The patient management system may include a data server communicating with the therapy device(s). The data server may compute, from therapy data, therapy summary data for the session, the summary data may include one or more statistics summarising therapy data. The patient management system may include a therapy management server communicating with the data server. The therapy management server may apply one or more rules to the summary data, update or generate one or more workflow groups of patients, each workflow group corresponding to a rule, depending on results of the respective rule applications; and/or serve a graphical layout representing one or more workflow groups.
Anaphylaxis and serious hypersensitivity reactions can occur in patients receiving ONCASPAR. The risk of serious hypersensitivity reactions is higher in patients with known hypersensitivity to (E.) coli derived L-asparaginase formulations. Other hypersensitivity reactions can include angioedema, lip swelling, eye swelling, erythema, blood pressure decreased, bronchospasm, dyspnea, pruritus, and rash [see Adverse Reactions (6.1)]. 

Premedicate patients 30-60 minutes prior to administration of ONCASPAR. [see Dosage and Administration (2.2)]. Observe patients for 1 hour after administration of ONCASPAR in a setting with resuscitation equipment and other agents necessary to treat anaphylaxis (for example, epinephrine, oxygen, intravenous steroids, antihistamines) [see Dosage and Administration (2.4)]. Discontinue ONCASPAR in patients with serious hypersensitivity reactions.
Although partial thickness rotator cuff tear prevalence is greater than those of full-thickness tear, most studies on conservative treatment are associated with full-thickness tears. In general, any physical therapy modality alone is not effective in the treatment of rotator cuff tears. It has been reported that multimodal physiotherapy may be more successful than monotherapy, but evidence in this regard is inadequate. Therefore this observational prospective study aiming to investigate the effectiveness of physiotherapy in the treatment of rotator cuff tears was planned. The null hypothesis of this study is that multimodal physical therapy combined with exercise has no effect on pain and function in the treatment of partial thickness rotator cuff tears. The alternative hypothesis is the opposite.

Patients will be assessed by standardized measures in terms of pain and function (American Shoulder and Elbow Surgeons standardized shoulder form: patient self report section), active range of motion (goniometric measurement) and quality of life (Western Ontario rotator cuff index) at baseline and first, third and 6th months of follow-up.
Preliminary investigations from our own research group showed that lung function parameters (FEV1, the FEV1/FVC ratio and a moderate to severe hyperresponsiveness to methacholine challenge were risk factors of asthma exacerbations (OR 11.3). In the present study, these parameters will be evaluated in prospective design.

One hundred children will be included in the study. Baseline parameters will be collected in a healthy interval (visit 1), then the children will be followed up for 1 year. If the patients fulfill the criteria for an exacerbation the children will present in our department. We expect that 44% of the children have an exacerbation. All children will present at a second visit after one year (visit 2).
As more people are doing regular exercises, people using protein supplements are also increasing. The effects of these substances on blood lipid profiles, biochemical, hematological parameters, inflammatory and glucose metabolism markers are not well known. So the investigators of this study planned to search the effects of these substances on blood tests. Totally 69 subjects going to the gym for at least three preceding months were included to the study. They were divided into two groups: the ones using protein supplements and the ones who never used these substances. Demographic and clinical characteristics were recorded. Dietician assessed the dietary habits of the subjects. Blood was drawn for the tests mentioned above from all of the subjects. And the results were compared between the two groups.
Baduanjin exercise as MICT will be applied with the same program duration and frequency as the HIIT group. The entire set of Baduanjin Qigong exercises in the current study includes 8 postures.
This an open-label, randomized study. Approximately 40 stable bipolar patients who are on an atypical antipsychotic (olanzapine, risperidone, quetiapine) plus adjunct bipolar treatment consisting of (a maximum or two of lithium, valproate or lamotrigine, and, if applicable, one antidepressant) will be randomized to two arms. In one arm, 25 milligrams of long-acting injectable risperidone will replace the oral atypical antipsychotic as adjunct therapy and in the other arm, patients will continue with their current atypical antipsychotic therapy. Trial duration is 6 months. In the long-acting injectable risperidone arm, the oral atypical antipsychotic will be continued (as supplementation) for 3 weeks after the first injection of long-acting risperidone and then discontinued. Investigators, based upon the patient's response, may increase the dose of injectable risperidone to 37.5 mg after 6 weeks on the 25-mg dose and to 50 mg after at least 4 weeks on the 37.5-mg dose. Risperidone oral supplementation is allowed. In the oral antipsychotic only arm, the oral atypical antipsychotic dose can also be increased as required. The primary efficacy outcome will be measured by changes in the Clinical Global Impression - Severity of Illness subscale (CGI-S), from baseline to endpoint, and will be compared between the treatment groups. Safety will be monitored throughout the study. The primary hypothesis is that patients switched to long-acting injectable risperidone will be able to tolerate this formulation of risperidone and maintain or even improve their reduction in bipolar symptomatology compared with baseline, and compared with subjects who continue in the oral antipsychotic arm. The secondary hypothesis is that patients switched to long-acting injectable risperidone will have a longer time to intervention for a mood episode (either mania or depression) as compared with subjects who continue in the oral antipsychotic arm. Risperidone, formulated for intramuscular injection, 25 mg every 2 weeks. Patients treated with injectable risperidone continue their original oral atypical antipsychotic (AAP) dose for 3 weeks. Investigators, at their discretion, may increase the dose of injectable risperidone to 37.5 mg after 6 weeks on the 25-mg dose and to 50 mg after at least 4 weeks on the 37.5-mg dose. Study duration is 6 months.
BACKGROUND: Hepatocellular carcinoma (HCC) ranks third in cancer-related deaths globally. Despite treatment advances, high post-hepatectomy recurrence rates (RR), especially with liver fibrosis and hepatitis C virus infection, remain challenging. Key prognostic factors include vascular invasion and perioperative blood loss, impacting extrahepatic recurrence. Natural killer (NK) cells are crucial in countering circulating tumor cells through TRAIL-mediated pathways. The aim of this study was to validate the liver immune status index (LISI) as a predictive tool for liver NK cell antitumor efficiency, particularly in HCC patients with vascular invasion.
METHODS: A retrospective analysis of 1337 primary HCC hepatectomies was conducted by the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO). Clinicodemographic data were extracted from electronic medical records. Prognostic indices (FIB-4, ALBI, ALICE, GNRI, APRI, and LISI) were evaluated using area under the receiver operating characteristic curve values. Survival analyses employed Kaplan-Meier estimations and log-rank tests.
RESULTS: LISI significantly correlated with other prognostic markers and stratified patients into risk groups with distinct overall survival (OS) and RR. It showed superior predictive performance for 2-year OS and RR, especially in patients with vascular invasion. Over longer periods, APRI and FIB-4 index reliabilities improved. The HISCO-HCC score, combining LISI, tumor burden score, and alpha-fetoprotein levels, enhanced prognostic accuracy.
CONCLUSION: LISI outperformed existing models, particularly in HCC with vascular invasion. The HISCO-HCC score offers improved prognostic precision, guiding immunotherapeutic strategies and individualized patient care in HCC.
Patients treated with IV tPA (intravenous tissue Plasminogen Activator) for acute stroke will be monitored in a non-ICU setting following the "Hopkins" post tPA monitoring protocol, a new schedule for vital signs and neurochecks. These patients will have vital signs and neurochecks every 15 minutes for two hours, then once upon admission to the stroke unit and after one hour, then every two hours for 8 hours and then every four hours until 24 hours post tPA.
A compound comprising a superoxide oxidant or reductant to which is directly or indirectly linked an NO or NO2 group. More particularly, compounds having the formula: D-X-R, wherein R is a moiety that oxidizes and/or reduces superoxide to oxygen and/or hydrogen peroxide under physiological conditions; X is S, N, O or C; and D is NO or NO2. R can be a functionality containing an unpaired electron, a cation such as a physiologically acceptable metal ion, hydrogen or a protective group or R can be a complex of a transition metal and a macrocyclic ligand that dismutes superoxide under physiological conditions. These compounds can be used alone or in combination or concurrently with other therapeutic agents, particularly nitric oxide adducts. Further, the invention provides that the superoxide oxidants or reductants which have not been linked to an NO or NO2 group can be administered in combination or concurrently with nitric oxide or nitric oxide adducts. They are useful for preventing superoxide cell damage and for treating inflammatory disorders in mammals, particularly humans.
While most rotary engines use the principle of volume variation between a curve and a moving cord of fixed length, this new engine concept uses a four degrees of freedom X, Y, .theta., .PHI. rotor, confined inside an internal housing contour wall, and does not require a central power shaft or support. The invention is an assembly of four carriages supporting the ends pivots of four pivoting blades forming a variable-shape rotor. This rotor rolls just like a roller bearing un the surface of an internal housing contour wall shaped like a skating rink. During the rotation, the rotor pivoting blades align alternatively in a lozenge and a square configuration. All ports are radial in the housing and/or axial on the lateral side covers. Since the compression and expansion strokes start and end simultaneously, an ignition flame transfer slot is used to maintain a continuous combustion while four strokes are completed in every rotation. A  central power shaft is not needed for the engine to operate, but can be added and driven by the blades, through mechanical coupling arms. The rotary engine incorporates few parts, does not need a crankshaft or a flywheel, and can be made strong enough to meet the criteria of photo-detonation and direct hydrogen combustion.